Leonard, Saskia
Jones, Alyssa N.
Newman, Lisa
Chavez-MacGregor, Mariana
Freedman, Rachel A.
Mayer, Erica L.
Mittendorf, Elizabeth A.
King, Tari A.
Kantor, Olga http://orcid.org/0000-0001-8699-7208
Article History
Received: 22 February 2024
Accepted: 17 March 2024
First Online: 23 April 2024
Declarations
:
: ELM reports consulting roles for Lilly, AstraZeneca, and Novartis. EAM reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Exact sciences (formerly Genomic Health), Merck, Moderna, Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. She receives research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor. She also reports uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports speaker honoraria and compensated service on scientific Advisory Board of Exact Sciences. She is also a Senior Associate Editor for Breast Cancer Research and Treatment. MCM reports consulting for Exact Sciences, Pfizer, Roche, Astra Zeneca, Lilly, Novartis, and Abbott; and research support from Novartis and Pfizer. LAN reports research support from Genentech. The remaining authors have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Brigham and Women’s Hospital.